Follow the people · Insider
Kathryn Guarini
Kathryn Guarini files insider transactions with the SEC as a director of Regeneron Pharmaceuticals (REGN). We hold 2 disclosed purchases and sales filed since 12 September 2023, 2 of them in the last 90 days.
- Files forREGN
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure3 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 8 September 2023 — 2 September 2026Director · Regeneron Pharmaceuticals (REGN)16 Form 4 lines · source: SEC Form 4
Everything they disclosed
16 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 400 shares of Regeneron PharmaceuticalsSEC Form 43 September 2026Common Stock · traded 2 September 2026 · filed 3 September 2026
- ▼ sold on the open market 400 shares of Regeneron PharmaceuticalsSEC Form 43 September 2026Common Stock · traded 2 September 2026 · filed 3 September 2026
- exercised options over 400 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 43 September 2026Non-Qualified Stock Option (right to buy) · traded 2 September 2026 · filed 3 September 2026
- exercised options over 400 shares of Regeneron PharmaceuticalsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 400 shares of Regeneron PharmaceuticalsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- exercised options over 400 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 412 August 2026Non-Qualified Stock Option (right to buy) · traded 10 August 2026 · filed 12 August 2026
- was granted 155 shares of Regeneron PharmaceuticalsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 1,962 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2026Non-Qualified Stock Option (right to buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 1,962 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2026Non-Qualified Stock Option (right to buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 155 shares of Regeneron PharmaceuticalsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 1,958 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2025Non-Qualified Stock Option (right to buy) · traded 2 January 2025 · filed 6 January 2025
- was granted 166 shares of Regeneron PharmaceuticalsSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 508 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 44 January 2024Non-Qualified Stock Option (right to buy) · traded 2 January 2024 · filed 4 January 2024
- was granted 42 shares of Regeneron PharmaceuticalsSEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- was granted 2,739 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 412 September 2023Non-Qualified Stock Option (right to buy) · traded 8 September 2023 · filed 12 September 2023
- was granted 240 shares of Regeneron PharmaceuticalsSEC Form 412 September 2023Common Stock · traded 8 September 2023 · filed 12 September 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.